Editorial & Columns Asset Swapping or Asset Trade in Pharmaceutical Industry March 27, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Make in India: PLI for Pharmaceutical Industry February 11, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Trump, PEPFAR and Indian Pharmaceutical Industry January 30, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Union Budget 2025: Expectations of Pharmaceutical Industry January 24, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Indian Pharmaceutical Industry in Consolidation Mode November 27, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Employment Dynamics in Indian Pharmaceutical Industry October 16, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Voluntary Licensing in Pharmaceutical Industry: Impact on Market Access & Pricing August 1, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Divestitures in Pharmaceutical Industry: Indian Experience July 25, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Spin-off by Pharmaceutical Companies in India: Improved Focus and Valuation July 11, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Competitive Intelligence in Pharmaceutical Industry July 6, 2024 | Dr. Anil Kumar Angrish | No Comments | More